Novo Nordisk is to cut 11 per cent of jobs and has reduced its profit guidance for this year, as the Danish maker of weight-loss drugs Ozempic and Wegovy struggles to fend off competition from US rival Eli Lilly.
諾和諾德(Novo Nordisk)將裁員11%，并下調今年的利潤指引。這家生產減肥藥諾和泰(Ozempic)和諾和盈(Wegovy)的丹麥公司正在努力抵御來自美國競爭對手禮來(Eli Lilly)的競爭。
您已閱讀8%（315字），剩余92%（3461字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。